Sabin Delivers Marburg Vaccines to Combat Outbreak in Rwanda
Sabin has provided its investigational Marburg vaccine to Rwanda to support the ongoing outbreak response. The initial shipment of approximately 700 vaccine doses will be used in a trial targeting frontline workers, including healthcare professionals who have been hardest hit by the deadly virus.
Now Accepting Nominations for 2025 Gold Medal and Rising Star Award
We invite you to nominate candidates whose contributions to immunology and public health deserve to be recognized by our highest scientific honor. Learn more.
Q&A: The Rising Threat of Measles and Vaccine Hesitancy
Sabin Gold Medal winner Dr. Paul Offit highlights the growing threat of measles fueled by vaccine hesitancy and stresses the urgent need for clear communication, education, and public trust to boost immunization efforts and curb outbreaks.
Confronting Deadly Diseases
Vaccines are our best defense against disease. Yet, we still have lethal diseases that need a vaccine solution urgently. Sabin’s R&D team is tackling two such threats: Sudan ebolavirus and Marburg virus disease. There are no approved vaccines for either of these viruses which have left behind a trail of outbreaks, ending many lives and livelihoods in Africa. Sabin’s vaccines are in Phase 2 clinical trials in Uganda and Kenya.
Making a Case for Vaccines
We make vaccines more accessible, enable innovation and expand immunization across the globe.